Published: 2018-11-22

Fibrinogen levels in type II diabetes mellitus patients with microvascular complications

Vijayalakshmi Chikkamath, Arathi Darshan, Jayaprakash S. Appajigol, Naveen Angadi, Abhishek T. G.


Background: Diabetes increases the morbidity and mortality due to its propensity to develop micro and macrovascular complications. Recently the role of haemostatic factors, particularly fibrinogen, in atherosclerosis and its complications has invited considerable attention. The present study was conducted to study plasma fibrinogen levels in type II diabetes mellitus patients with microvascular complications.

Methods: One hundred patients aged 18years to 60years with type 2 diabetes mellitus with microvascular complications were included in the study. HBA1c, plasma fibrinogen, urine routine examination, fundoscopy, monofilament testing, FBS, PPBS were done. Descriptive statistics was used to analyse data.

Results: Out of 100 diabetes patients with microvascular complication studies, 88 patients were found to have hyperfibrinogenaemia. Out of 100 patients 67 patients had HbA1c of more than 8%, and all of them had elevated fibrinogen levels (p <0.0001). The prevalence of hyperfibrinogenemia was higher in patients with diabetic retinopathy (90%), when compared to those without diabetic retinopathy (83.33%) although it was statistically not significant (p=0.266).

Conclusions: Hyperfibrinogenemia among type 2 diabetes mellitus patients with microvascular complications was high. Glycaemic control has a significant impact on the fibrinogen levels. Longer the duration of diabetes, there was a higher prevalence of hyperfibrinogenemia.


Diabetes, Hyperfibrinogenemia, Microvascular complications

Full Text:



Alvin C Power. Diabetes mellitus. In: Kasper DL, Braunwald E, Fauci A, Hauser S, Longo D Jameson JL (eds.). Harrison’s Principle of Internal Medicine. 16.ed. McGraw-Hill, 2004; pp. 3779–829

Alvin CP (2001). Diabetes Mellitus. In: Braunwald E, Faucei AS, Kasper DL, Hauser SL, Longo DL, Larry JJ (eds) Harrison’s principles of internal medicine, 15th edn. McGraw Hill Medical Publishing division, New York, pp 2109–2137.

Mark A, Thomas F. Diabetes and vascular disease pathophysiology clinical consequences and medical therapy: Part I. Circulation.2003; 108: 1527-1532.

Bruno G, Cavallo-perin P, Bargero G, Borra M, Errico ND,Pagano G. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-Insulin-dependent diabetes mellitus. Ann Intern Med.1996. 125:653–657.

Fuller JH, Keen H, Jarrett RJ, Omer T, Meade TW, Charkrabarti R. Haemostatic variables associated with diabetes and its complications. Br Med J 1979;2:964–966.

Kannel BW, Wilson WF, Belanger AJ, Gagnon Dr, D’Agostino BD. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. JAMA. 1987;258:1183–1186.

Vekasi J, Marton ZS, Kesmarky G, et al. Hemorheological alterations in patients with diabetic retinopathy. ClinHemorheolMicrocirc. 2001 ;24:59-64.

Shin S, Ku Y, Babu N, et al. Erythrocyte deformability and its variation in diabetes mellitus. Indian J ExpBiol.2007; 45:121-8.

Klein RL, Hunter SJ, Jenkins AJ, et al; Dcct/Ecic Study Group. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care 2003; 26:1439-48.

Ajjan R, Grant PJ. Coagulation and atherothrombotic disease. Atherosclerosis.2006;186:240–59.

Ceriello A, Giacomello R, Stel G, et al. Hyperglycemia induced thrombin formation in diabetes: a possible role of oxidative stress. Diabetes.1995 ;44:924-928.

De Feo P, Gaisano MG, Haymond MW. Differential effects of insulin deficiency on albumin and fibrinogen synthesis in humans. JClin Invest. 1991 ;88(3):833-40.

Fujii C, Sakakibara H, Kondo T, Yatsuya H et al. Plasma fibrinogen levels and cardiovascular risk factors in Japanese school children. J Epidemiol. 2006 and 16(2):64-70.

Neetha Kuzhuppily IR, VijayaPaaai H. Plasma fibrinogen levels and its relation to diabetic retinopathy. Kerala Journal of Ophthalmology. 2010 and XXII(4):339-345.

Frank RN, Hoffman WH, Podgor MJ, et al. Retinopathy in juvenile onset type I diabetes of short duration. Diabetes 1982 and 31:874-82.

Palmberg P, Smith M, Waltman S, et al. The natural history of retinopathy in insulin-dependent juvenile-onset diabetes. Ophthalmology 1981 and 88:613-8.